Akebia Therapeutics Stock News

Under any circumstance, penny stocks are extremely risky. However, their under-the-radar profile could be intriguing right now.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak''s Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences Inc. (Nasdaq: KOD ) announced negative top-line results from its Phase 2b/3 clinical trial evaluating the KSI-301 in treatment-naïve subjects with neovascular age-related macular degeneration. The study did not meet the primary efficacy endpoint of showing non-inferior visual acuity gains for subjects dosed on extended regimens compared to aflibercept given every eight weeks. The stock was sinking 70.86% to $14.67 in premarket trading. Akebia''s Announces Expanded Agreement With Vifor Regarding Marketing Of Its Kidney Disease Drug Akebia Therapeutics, Inc. (NASDAQ: AKBA ) and Vifor Pharma AG (OTC: GNHAF ) announced that the companies have amended and restated the terms of their license agreement. Under the amended agreement Akebia granted Vifor an exclusive license to sell vadadustat, its investigational oral therapeutic for the treatment of anemia due to chronic kidney disease, to Fresenius Medical Care North America, subject to vadadustat''s approval by the U.S.

Akebia Therapeutics (AKBA) amended a license agreement with Vifor Pharma (GNHAF) for the former''s vadadustat, a potential treatment for anemia due to chronic kidney disease.

CAMBRIDGE, Mass., Feb. 9, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year 2021…

The AKEBIA THERAPEUTICS INC POLITICAL ACTION COMMITTEE successfully filed their F3XN QUATERLY YEAR-END with the coverage period of 07/01/2021 to 12/31/2021 and a confirmation ID of FEC-1562741 *********CommitteeId: C00684126 | FilingId: 1562741 | FormType: F3XN | CoverageFrom: 07/01/2021 | CoverageThrough: 12/31/2021 | ReportType: QUATERLY YEAR-END*********

Akebia Therapeutics Inc. (AKBA) shares closed today at 0.9% above its 52 week low of $2.19, giving the company a market cap of $386M. The stock is currently down 2.2% year-to-date, down 28.7% over the past 12 months, and down 79.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 27.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 734.7% The company's stock price performance over the past 12 months lags the peer average by 462.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Virginia Retirement Systems ET AL lifted its position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 181.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 158,800 shares of the biopharmaceutical companys stock after acquiring an additional 102,400 shares during the period. []

In today’s recent session, 0.77 million shares of the Akebia Therapeutics Inc. (NASDAQ:AKBA) have been traded, and its beta is 1.56. Most recently the company’s share price was $2.54, and it changed around $0.04 or 1.40% from the last close, which brings the market valuation of the company to $462.30M. AKBA at last check was … Akebia Therapeutics Inc.: Why Investors Shouldn’t Get Rid Of AKBA Stock In 2021 Read More »

The trading price of Akebia Therapeutics Inc. (NASDAQ:AKBA) closed lower on Friday, December 10, closing at $2.50, -1.96% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

New Jersey, United States,- Verified Market Research has recently published a research report titled, Phosphate Binders Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to formulate

Akebia Therapeutics Inc. (NASDAQ:AKBA) price on Wednesday, December 08, fall -0.37% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.70. A look at the stock’s price movement, the close in the last trading session was $2.71, moving within a range at $2.63 and $2.731. The beta value … Do Akebia Therapeutics Inc. (NASDAQ: AKBA) Provide Stability And Growth? Read More »

Metropolitan Life Insurance Co NY raised its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 63,434.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,955 shares of the biopharmaceutical companys stock after purchasing an additional 27,911 shares during the []

Akebia Therapeutics Inc. (NASDAQ:AKBA) has a beta value of 1.56 and has seen 2.38 million shares traded in the last trading session. The company, currently valued at $462.63M, closed the last trade at $2.67 per share which meant it lost -$0.12 on the day or -4.30% during that session. The AKBA stock price is -92.51% Bears Are Back On The Defensive As Akebia Therapeutics Inc. (AKBA) tumbled -4.30% Read More »

California State Teachers Retirement System grew its stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 2.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 220,205 shares of the biopharmaceutical companys stock after purchasing an additional 4,245 shares during the period. California []